Publicaciones en colaboración con investigadoras/es de Universidad de Oviedo (8)

2016

  1. Estudio retrospectivo de diferentes opciones de tratamiento conservador con Bacilo de Calmette-Guèrin en el carcinoma urotelial vesical T1G3: terapia de mantenimiento

    Actas Urologicas Espanolas, Vol. 40, Núm. 6, pp. 370-377

  2. The IASLC lung cancer staging project: Proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM Classification for lung cancer

    Journal of Thoracic Oncology, Vol. 11, Núm. 1, pp. 39-51

2014

  1. Influencia del número real de instilaciones de Bacilo de Calmette-Guérin aplicadas en el pronóstico de los tumores vesicales no músculo-infiltrantes

    Actas Urologicas Espanolas, Vol. 38, Núm. 5, pp. 280-284

2011

  1. The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: External validation of the EORTC risk tables

    European Urology, Vol. 60, Núm. 3, pp. 423-430

  2. The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscleinvasive bladder cancer treated with bacillus Calmette-Guérin: External validation of the EORTC risk tables

    International Braz J Urol

2009

  1. LONG-TERM FOLLOW UP OF THE EFFECTIVENESS OF STANDARD DOSE BCG (81 MG. CONNAUGHT STRAIN) COMPARING WITH A THREE FOLD REDUCE DOSE (27 MG.) IN HIGH RISK NON MUSCLE INVASIVE BLADDER CANCER. CUETO GROUP

    EUROPEAN UROLOGY SUPPLEMENTS

  2. Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in Patients Treated With Bacillus Calmette-Guerin: The CUETO Scoring Model

    Journal of Urology, Vol. 182, Núm. 5, pp. 2195-2203

2008

  1. Prognostic Factors in Patients with Non-Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin: Multivariate Analysis of Data from Four Randomized CUETO Trials

    European Urology, Vol. 53, Núm. 5, pp. 992-1002